These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure. Ueda N; Kato H; Kato S; Saito T; Tachibana H; Yanada M; Taji H; Kodaira T; Hosoda W; Yamamoto K Hematology; 2023 Dec; 28(1):2207946. PubMed ID: 37183912 [TBL] [Abstract][Full Text] [Related]
26. How I incorporate novel agents into the treatment of classical Hodgkin lymphoma. Epperla N; Herrera AF Blood; 2021 Aug; 138(7):520-530. PubMed ID: 33889927 [TBL] [Abstract][Full Text] [Related]
27. Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature. Nagaharu K; Masuya M; Kageyama Y; Yamaguchi T; Ito R; Kawakami K; Ito M; Katayama N J Med Case Rep; 2018 May; 12(1):151. PubMed ID: 29843820 [TBL] [Abstract][Full Text] [Related]
28. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. Fornecker LM; Lazarovici J; Aurer I; Casasnovas RO; Gac AC; Bonnet C; Bouabdallah K; Feugier P; Specht L; Molina L; Touati M; Borel C; Stamatoullas A; Nicolas-Virelizier E; Pascal L; Lugtenburg P; Di Renzo N; Vander Borght T; Traverse-Glehen A; Dartigues P; Hutchings M; Versari A; Meignan M; Federico M; André M; J Clin Oncol; 2023 Jan; 41(2):327-335. PubMed ID: 35867960 [TBL] [Abstract][Full Text] [Related]
29. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. Ansell SM; Radford J; Connors JM; Długosz-Danecka M; Kim WS; Gallamini A; Ramchandren R; Friedberg JW; Advani R; Hutchings M; Evens AM; Smolewski P; Savage KJ; Bartlett NL; Eom HS; Abramson JS; Dong C; Campana F; Fenton K; Puhlmann M; Straus DJ; N Engl J Med; 2022 Jul; 387(4):310-320. PubMed ID: 35830649 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis. Raymakers AJN; Costa S; Cameron D; Regier DA BMC Cancer; 2020 Oct; 20(1):992. PubMed ID: 33050897 [TBL] [Abstract][Full Text] [Related]
31. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma]. Maruyama D Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053 [TBL] [Abstract][Full Text] [Related]
32. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report. Gunes AK; Demir I; Pehlivan M J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294 [TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan. Tien FM; Tsai CH; Liu JH; Lin CT J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522 [TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649 [TBL] [Abstract][Full Text] [Related]
35. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420 [TBL] [Abstract][Full Text] [Related]
36. Combining Brentuximab Vedotin With Dexamethasone, High-dose Cytarabine, and Cisplatin as Salvage Treatment in Pediatric Relapsed or Refractory Classic Hodgkin Lymphoma: Two Case Reports. Muggeo P; Sinisi C; Angarano R; Daniele RM; Grassi M; Ingravallo G; Santoro N J Pediatr Hematol Oncol; 2024 Aug; 46(6):e439-e442. PubMed ID: 38934587 [TBL] [Abstract][Full Text] [Related]
37. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731 [No Abstract] [Full Text] [Related]
38. The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series. McMillan A; O'Neill AT; Townsend W; Lambert J; Virchis A; Shah R; Menezes L; Humphries P; Von Both K; Grandage V; Carpenter B; Hough R; Ardeshna KM; Daw S Br J Haematol; 2021 Feb; 192(3):e84-e87. PubMed ID: 33426648 [No Abstract] [Full Text] [Related]
39. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma]. Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698 [TBL] [Abstract][Full Text] [Related]
40. Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement. Mociková H; Malikova H; Holesta M; Elturki A; Campr V; Kozak T Am J Case Rep; 2020 Mar; 21():e921657. PubMed ID: 32170052 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]